APA (7th ed.) Citation

Wanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., . . . Zinman, B. (2018). Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation (New York, N.Y.), 137(2), 119-129. https://doi.org/10.1161/CIRCULATIONAHA.117.028268

Chicago Style (17th ed.) Citation

Wanner, Christoph, et al. "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease." Circulation (New York, N.Y.) 137, no. 2 (2018): 119-129. https://doi.org/10.1161/CIRCULATIONAHA.117.028268.

MLA (9th ed.) Citation

Wanner, Christoph, et al. "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease." Circulation (New York, N.Y.), vol. 137, no. 2, 2018, pp. 119-129, https://doi.org/10.1161/CIRCULATIONAHA.117.028268.